☆ 4.1 Article

Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2012)

Journal

INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Volume 50, Issue 1, Pages 76-78

Publisher

DUSTRI-VERLAG DR KARL FEISTLE

DOI: 10.5414/CPP50076

Keywords

Phase I study; Atu027; siRNA; PKN3

Categories

Pharmacology & Pharmacy

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.